tickrz reports
  
tickrz rank
B
Biogen Inc (BIIB)
Healthcare | Biotechnology
CEO: Michel Vounatsos
Employees: 7350
biogen.com
FACTOR RANKINGSFACTOR SCREENER 
Pure Value Rank241Dividend RankNO DIVIDEND
Moat Rank15Financial Strength Rank172
Growth Rank17Momentum Rank238
DIVIDEND ANALYSIS
Dividend Yield0%
Payout Ratio8.71%
3 yr Dividend GrowthN/A
VALUATION RATIOS
P/E Ratio15.52x
P/B Ratio4.7x
P/S Ratio4.68x
EV/EBITDA Ratio9.72x
FINANCIAL STRENGTH
Piotroski F-Score5
Debt-to-Equity57%
Interest Coverage0x
MOAT
ROE31.88%
ROIC32.43%
Net Margin36.32%
GROWTH
5 yr EPS Growth27.41%
5 yr SPS Growth19.33%
5 yr BPS Growth16.2%
Biogen Inc 's strong growth translates to a Growth Rank in the top 25% of all stocks
 tickrz summary
Biogen Inc receives a B ranking in our proprietary ranking system that combines valuation, moat, operational performance, and financial strength. View the Top 50 tickrz ranked stocks here.
 value
 pure value ranking Warren Buffett ranking
Valuation is the most heavily weighted component in our tickrz ranking methodology. Numerous academic and practitioner studies have found that a value approach outperforms the market over the long-run. Biogen Inc's valuation score is comprised of a P/E ratio of 15.5x, a P/B ratio of 4.7x, a P/S ratio of 4.7x, and an EV/EBITDA ratio of 9.7x. Biogen Inc ranks 241 out of the S&P 500 constituents on valuation--a relatively average score.Biogen Inc ranks 40 out of the S&P 500 constituents in our multi-factor Warren Buffett ranking methodology. This is a strong score, meaning it ranks highly on valuation, moat, volatility, and financial strength factors. If you're looking for undervalued stocks with high moats and strong competitive advantages, Biogen Inc warrants further investigation.

 quality
 moat financial strength
To calculate a company's Moat Score, we look at its historical earnings growth, historical average return on equity, the volatility of its earnings stream, and also factor in the strength of its balance sheet. Our approach concludes the company's business moat is strong. Biogen Inc appears to have a durable competitive advantage within the Healthcare sector. Biogen Inc has a Piotroski F Score of 5 out of 9. The F Score examines changes in profitability, leverage, liquidity, and operating efficiency. Interest coverage of 0x, a debt/equity ratio of 57% and a Moat Rank of 15 translate to an average Financial Strength score.


 momentum
Investment research has shown that stocks with strong performance over the last 6 to 12 months tend to perform better in the medium term than stocks with poor performance over the same period. In fact, the momentum factor is one of the strongest of all the investment factors. The company has seen its stock appreciate by 14.11% over the last 12 months. This performance is average compared to other stocks in the S&P 500, earning it a rank of 238. Based on its 12 month stock performance, Biogen Inc will not appeal to momentum investors.

 yield
 value + yield
Biogen Inc currently does not pay a dividend so it ranks last among S&P 500 companies using our dividend ranking methodology. Investors looking for undervalued dividend stocks will probably want to look elsewhere.

 growth
A company's growth metrics are less important than its valuation, moat, and financial strength. However, a check on growth can be a good way to avoid companies in secular decline. The company's growth in sales, earnings, and book value places it among the top third of S&P 500 companies. Its 27.4% 5 year annualized EPS growth, 19.3% 5 year annualized sales-per-share growth, and 5 year annualized book value-per-share growth of 16.2% speak to its impressive growth ranking.

Biogen Inc (BIIB)
Healthcare | Biotechnology
CEO: Michel Vounatsos
Employees: 7350
biogen.com


tickrz rank
B

VALUATION RATIOS
P/E Ratio15.52x
P/B Ratio4.7x
P/S Ratio4.68x
EV/EBITDA Ratio9.72x
DIVIDEND ANALYSIS
Dividend Yield0%
Payout Ratio8.71%
3 yr Dividend GrowthN/A
FINANCIAL STRENGTH
Piotroski F-Score5
Debt-to-Equity57%
Interest Coverage0x
MOAT
ROE31.88%
ROIC32.43%
Net Margin36.32%
GROWTH
5 yr EPS Growth27.41%
5 yr SPS Growth19.33%
5 yr BPS Growth16.2%

TICKRZ RANK
Biogen Inc receives a B ranking in our proprietary ranking system that combines valuation, moat, operational performance, and financial strength. View the Top 50 tickrz ranked stocks here.

PURE VALUE
Valuation is the most heavily weighted component in our tickrz ranking methodology. Numerous academic and practitioner studies have found that a value approach outperforms the market over the long-run. Biogen Inc's valuation score is comprised of a P/E ratio of 15.5x, a P/B ratio of 4.7x, a P/S ratio of 4.7x, and an EV/EBITDA ratio of 9.7x. Biogen Inc ranks 241 out of the S&P 500 constituents on valuation--a relatively average score.

WARREN BUFFETT RANKING
Biogen Inc ranks 40 out of the S&P 500 constituents in our multi-factor Warren Buffett ranking methodology. This is a strong score, meaning it ranks highly on valuation, moat, volatility, and financial strength factors. If you're looking for undervalued stocks with high moats and strong competitive advantages, Biogen Inc warrants further investigation.

MOAT
To calculate a company's Moat Score, we look at its historical earnings growth, historical average return on equity, the volatility of its earnings stream, and also factor in the strength of its balance sheet. Our approach concludes the company's business moat is strong. Biogen Inc appears to have a durable competitive advantage within the Healthcare sector.

FINANCIAL STRENGTH
Biogen Inc has a Piotroski F Score of 5 out of 9. The F Score examines changes in profitability, leverage, liquidity, and operating efficiency. Interest coverage of 0x, a debt/equity ratio of 57% and a Moat Rank of 15 translate to an average Financial Strength score.

MOMENTUM
Investment research has shown that stocks with strong performance over the last 6 to 12 months tend to perform better in the medium term than stocks with poor performance over the same period. In fact, the momentum factor is one of the strongest of all the investment factors. The company has seen its stock appreciate by 14.11% over the last 12 months. This performance is average compared to other stocks in the S&P 500, earning it a rank of 238. Based on its 12 month stock performance, Biogen Inc will not appeal to momentum investors.

VALUE + YIELD
Biogen Inc currently does not pay a dividend so it ranks last among S&P 500 companies using our dividend ranking methodology. Investors looking for undervalued dividend stocks will probably want to look elsewhere.

GROWTH
A company's growth metrics are less important than its valuation, moat, and financial strength. However, a check on growth can be a good way to avoid companies in secular decline. The company's growth in sales, earnings, and book value places it among the top third of S&P 500 companies. Its 27.4% 5 year annualized EPS growth, 19.3% 5 year annualized sales-per-share growth, and 5 year annualized book value-per-share growth of 16.2% speak to its impressive growth ranking.